Tnf Pharmaceuticals, INC 8-K filings

MyMD Pharmaceuticals announces the immediate resignation of its Chief Scientific Officer, Adam Kaplin, M.D., Ph.D., effective April 15, 2024.

MyMD Pharmaceuticals has amended the terms of its Series F Convertible Preferred Stock, deferring installment payments and granting preferred shareholders the right to elect a board member.

MyMD Pharmaceuticals filed an amendment to its previous 8-K report to correct a typographical error regarding the number of authorized shares.

MyMD Pharmaceuticals, Inc. has completed its reincorporation from New Jersey to Delaware, effective March 4, 2024.

MyMD Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement after a reverse stock split.

MyMD Pharmaceuticals has announced a 1-for-30 reverse stock split of its common stock, effective February 14, 2024, to maintain its Nasdaq listing.